J Cancer 2016; 7(12):1740-1746. doi:10.7150/jca.15620

Research Paper

MiR-193a-5p Targets the Coding Region of AP-2α mRNA and Induces Cisplatin Resistance in Bladder Cancers

Ji Zhou1, Huaxin Duan2, Yu Xie3, Yichong Ning1, Xing Zhang1, Na Hui1, Chunqing Wang1, Jian Zhang1, Jianlin Zhou1✉

1. College of Life Science, Hunan Normal University, Changsha 410081, Hunan, China;
2. Hunan Provincial People's Hospital, Changsha 410005, Hunan, China
3. Hunan Cancer Hospital, Changsha 410013, Hunan, China.


Transcription factor AP-2 alpha (AP-2α or TFAP2A) is a newly identified prognostic marker of chemotherapy; its expression is positively correlated with chemosensitivity and survival of cancer patients. Using computational programs, we predicted that the coding region of AP-2α gene contains a potential miRNA response element (MRE) of miR-193a-5p, and the single nucleotide polymorphism (SNP) site (c.497A>G, rs111681798) resides within the predicted MRE. The results of luciferase assays and Western blot analysis demonstrated that miR-193a-5p negatively regulated the expression of AP-2α proteins, but have no influence on the mutant AP-2α (c.497A>G). Infection with lentiviral AP-2α gene or miR-193a-5p inhibitor in the bladder cancer cells decreased migration and cisplatin resistance, while knockdown of AP-2α gene or overexpression of miR-193a-5p in the urothelial cell line SV-HUC-1 increased migration and cisplatin resistances. We concluded that miR-193a-5p induced cisplatin resistance by repressing AP-2α expression in bladder cancer cells.

Keywords: miR-193a-5p, AP-2α, cisplatin resistance, bladder cancer, single nucleotide polymorphism.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Zhou J, Duan H, Xie Y, Ning Y, Zhang X, Hui N, Wang C, Zhang J, Zhou J. MiR-193a-5p Targets the Coding Region of AP-2α mRNA and Induces Cisplatin Resistance in Bladder Cancers. J Cancer 2016; 7(12):1740-1746. doi:10.7150/jca.15620. Available from http://www.jcancer.org/v07p1740.htm